← Leaderboards
Jonathan M Kimmelman
University Of California At Davis
$826,217
Attributed
$1,652,433
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $645.3K · FY2022–24$1M$750K$500K$250K$0
'22
'23
'24
Funding mix
By agency
NIH$1,652,433 · 1
By mechanism
R01$1,652,433 · 1
Top collaborators
- Mark Yarborough2 shared
- Mark Fedyk1 shared
Most similar at University Of California At Davis
Same institution · by research overlap
- Meir Bialer$1,012,233
- Mark Yarborough$600,431
- Mark Fedyk$225,786
- Dennis Michael Styne$1,000,000
- Simon Benjamin Ascher$191,777
Others in their field
Other Rising Stars on “Benefits And Risks”
- Sabrina Paganoni · Massachusetts General Hospital$11,004,714
- Suma Babu · Massachusetts General Hospital$11,004,714
- Robert C Alexander · Banner Health$8,197,111
- Matthew Morrow Engelhard · Duke University$7,519,665
- Andrew Gardiner · Libero Pharma Limited$6,351,015
- Michele Caggana · Nysdoh/Health Research, Inc.$4,856,614
Research focus
Benefits And RisksAuthorization DocumentationCharacteristicsClinical EfficacyBrainClinical TranslationCommon RuleComputer SoftwareCrispr/Cas TechnologyData AnalyticsDecision AidClinical ResearchDesignDisclosureEarly Phase TrialEffective TherapyEfficacy StudyEnrollmentEthicsFallsFutureInformed ConsentInstitutional Review BoardsInstruction
Grant awards (3)
The RATIOS Study: Risk/benefit AssessmenT by IRB review of Phase One Studies$451,572
R01 · FY2024 · NS
The RATIOS Study: Risk/benefit AssessmenT by IRB review of Phase One Studies$555,553
R01 · FY2023 · NS
The RATIOS Study: Risk/benefit AssessmenT by IRB review of Phase One Studies$645,308
R01 · FY2022 · NS